SeaStar Medical Holding Co. (NASDAQ:ICU) Short Interest Update

SeaStar Medical Holding Co. (NASDAQ:ICU) was the recipient of a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 209,300 shares, an increase of 356.0% from the August 15th total of 45,900 shares. Currently, 3.4% of the company’s shares are sold short. Based on an average daily volume of 321,500 shares, the days-to-cover ratio is presently 0.7 days.

Institutional Trading of SeaStar Medical

Institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC acquired a new stake in shares of SeaStar Medical during the fourth quarter worth $63,000. Two Sigma Securities LLC acquired a new stake in shares of SeaStar Medical during the second quarter worth $29,000. Finally, Hudson Bay Capital Management LP grew its position in shares of SeaStar Medical by 38.8% during the second quarter. Hudson Bay Capital Management LP now owns 346,972 shares of the company’s stock worth $178,000 after acquiring an additional 96,972 shares during the last quarter. 11.63% of the stock is owned by institutional investors and hedge funds.

SeaStar Medical Stock Performance

SeaStar Medical stock opened at $0.22 on Friday. SeaStar Medical has a 1 year low of $0.16 and a 1 year high of $22.00. The firm has a 50 day moving average price of $0.38 and a 200 day moving average price of $1.09.

SeaStar Medical (NASDAQ:ICU) last announced its earnings results on Monday, August 14th. The company reported ($0.25) earnings per share for the quarter.

SeaStar Medical Company Profile

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome.